Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth ...
Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter ...
Pfizer and Blackstone Life Sciences sign a co-funding deal in which Blackstone is set to provide up to $1.5 billion through 2028 to advance berobenatide.
FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention. FDA has granted ...
With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.
FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new ...
FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION.
A group of experts explore the advantages of purpose-built artificial intelligence (AI) for healthcare over generic models.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results